Yes! A positive Phase 3 treatment study for symptoms of dementia

By | Commentary, In the News

Contributed by David Sultzer, MD, Professor of Psychiatry & Human Behavior Last week, Acadia Pharmaceuticals announced findings from its trial of pimavanserin for treatment of delusions and hallucinations related to dementia: Participants treated with pimavanserin had better outcomes than those treated with placebo. The study design was different from usual treatment comparisons of drug and placebo.  In this trial, all participants with psychosis symptoms along with Alzheimer’s disease or another cognitive disorder were treated with pimavanserin for 12 weeks.  Those who showed improvement were then assigned to either continue taking the drug or cross over to placebo treatment.  The study…

Read More

Join us for a complimentary dinner and educational speaker at Villagio!

By | Community Events

ALZHEIMER’S DISEASE & DEMENTIA Wednesday, September 25th at 6:00PM Villagio at Capriana (454 S La Floresta Drive, Brea, CA 92823) Join us for a complimentary dinner and educational speaker at Villagio! William Edwards from UCI MIND will provide education on Alzheimer’s disease and dementia, risk and protective factors, and advances in research. Kindly RSVP to 714.985.5500 by September 23rd, as space is limited. About the Speaker: William Edwards was an Alzheimer’s caregiver for his wife, Nancy, for 12 years and now serves on the Leadership Council and Speakers Bureau for UCI MIND to help raise awareness and support for critical…

Read More

What lifestyle factors increase and decrease risk for Alzheimer’s disease?

By | Commentary, Community Events

What lifestyle factors increase and decrease risk for Alzheimer’s disease? October 25th Research Conference #SpeakerSpotlight: Dr. Rebecca Gottesman is a board-certified Neurologist and Professor of Neurology and Epidemiology at Johns Hopkins University. Her research focuses on the short-term and long-term cognitive effects of heart disease and stroke. She uses a combination of clinical studies in patients and epidemiological studies to evaluate the impact of heart disease on the brain. In the session, “Risk and Prevention Across the Lifespan,” Dr. Gottesman will discuss the link between heart health and brain health and identify lifestyle factors that increase and decrease risk for…

Read More

Another setback, yet another reason to redouble our efforts

By | In the News

Contributed by Joshua Grill, PhD, Director of UCI MIND Late Thursday evening, Esai publicly announced a decision to halt a Phase 3 clinical trial of a candidate treatment for Alzheimer’s disease, elenebecestat. The decision was made based on a recommendation by the study’s Data Safety Monitoring Board, which determined that the safety risks of the drug no longer justified continuing the study. Elenebecestat is a BACE (beta-site of the amyloid precursor protein cleavage enzyme) inhibitor that joins several other BACE inhibitors previously determined to lack adequate safety for patient use. The field will grapple with this news and learn how…

Read More

How can “smart” technology be used to detect cognitive problems?

By | Commentary, Community Events

How can “smart” technology be used to detect cognitive problems? October 25th Research Conference #SpeakerSpotlight: Dr. Rhoda Au is a Professor of Anatomy & Neurobiology, Neurology and Epidemiology at Boston University and has served as an investigator on the Framingham Heart Study since 1990, conducting research related to cognitive aging and dementia. Dr. Au’s research focuses on a how “bigdata” analytics can better inform our understanding of Alzheimer’s disease. In the session, “Detection in the Digital Era,” Dr. Au will discuss how innovative technology can be used to track cognitive performance in older adults. Attendees will learn how digital technologies…

Read More